705 results about "Vascular Disorder" patented technology

Systems and methods are disclosed for evaluating a patient with vascular disease. One method includes receiving patient-specific data regarding a geometry of the patient's vasculature; creating an anatomic model representing at least a portion of a location of disease in the patient's vasculature based on the received patient-specific data; identifying one or more changes in geometry of the anatomic model based on a modeled progression or regression of disease at the location; calculating one or more values of a blood flow characteristic within the patient's vasculature using a computational model based on the identified one or more changes in geometry of the anatomic model; and generating an electronic graphical display of a relationship between the one or more values of the calculated blood flow characteristic and the identified one or more changes in geometry of the anatomic model.

The invention relates to the technical field of health status assessment, in particular to a cardiovascular disease layered early warning system, which is characterized in that blood vessel compliance and pulse wave velocity are extracted, arterial dilation capacity is measured, blood vessel elasticity is calculated, blood perfusion distribution is detected, and abnormal vasoconstriction is classified on the basis of a hemodynamic state and a heart electrical activity state; in combination with the thickness of the blood vessel wall and the blood vessel stenosis rate, the plaque deposition condition is analyzed, the arteriosclerosis score is calculated, the thrombosis tendency is detected, the local blood flow blocking degree is quantified, the isolation forest algorithm is adopted, the blood flow dynamic change is calculated, the heart rhythm abnormality is analyzed, the acute vascular occlusion probability is measured, and the sudden heart rhythm abnormality risk is evaluated. And based on a gradient boosting tree algorithm, screening high-risk cases, matching medical intervention measures, setting a risk buffer mechanism, adjusting an individual health management strategy, and optimizing a cardiovascular risk hierarchical early warning system.

Systems and methods are disclosed for evaluating a patient with vascular disease. One method includes receiving patient-specific data regarding a geometry of the patient's vasculature; creating an anatomic model representing at least a portion of a location of disease in the patient's vasculature based on the received patient-specific data; identifying one or more changes in geometry of the anatomic model based on a modeled progression or regression of disease at the location; calculating one or more values of a blood flow characteristic within the patient's vasculature using a computational model based on the identified one or more changes in geometry of the anatomic model; and generating an electronic graphical display of a relationship between the one or more values of the calculated blood flow characteristic and the identified one or more changes in geometry of the anatomic model.

The invention relates to a cardiovascular disease risk prediction system, which comprises a user terminal module, an edge computing module, a cloud intelligent module, an application service module and a system support module, wherein the user terminal module comprises an intelligent sensing equipment cluster unit and a mobile terminal data entry unit; and the intelligent sensing equipment cluster unit adopts a millimeter wave radar-PPG fusion sensor, monitors subcutaneous 0.5 mm depth arterial vibration through a 60GHz radar array, is aligned with a photoplethysmogram signal in a space-time manner, and performs user data acquisition based on a surface plasma resonance chip. According to the cardiovascular disease risk prediction method and system, real-time signal processing is realized by adopting JetsonAGX through a heterogeneous calculation architecture, medical image accelerated calculation is performed by using NVIDIAClara, non-out-of-domain joint modeling of data of hospitals is supported through federal learning, privacy protection reasoning based on homomorphic encryption is realized, and full-process closed-loop management is realized by adopting a layered modular architecture. And the accuracy of cardiovascular disease risk prediction is improved.

The invention relates to lauroyl cilostazol as well as a preparation method and application thereof. Wherein the lauroyl cilostazol is sterile, and preferably, the lauroyl cilostazol is a crystal. The invention further provides application of the lauroyl cilostazol in preparing medicines for treating cerebral infarction, cerebrovascular diseases, atherosclerosis, diabetic complications, peripheral vascular diseases, Reynolds diseases, intermittent claudication, ischemic heart diseases and acute coronary syndromes. The lauroyl cilostazol has the remarkable long-acting characteristic.

The invention provides an echocardiogram video abstraction method based on a hierarchical space-time attention mechanism, and the method comprises the steps: obtaining an echocardiogram, inputting the echocardiogram into an anatomy and physiological basic model of a key frame recognition task, and obtaining key frame information; inputting the key frame information into a multi-dimensional spatial-temporal feature extraction model to obtain feature information and frequency domain information; fusing the feature information and the frequency domain information; performing key frame enhancement processing on the fusion information by adopting an SE channel attention mechanism to obtain key frame anatomical feature expression; processing the key frame anatomical feature expression by adopting a key frame backtracking strategy and a classification network to obtain a key frame identification classification result; performing left ventricle segmentation on the classified image by adopting an improved U-Net left ventricle region segmentation network; estimating the area and volume of the left ventricle based on a segmentation result; fusing the estimated left ventricular area and volume by adopting a hierarchical attention mechanism and a cross-layer information fusion strategy to obtain a ventricular volume result; according to the method, through abstract extraction of the key information of the ultrasonic cardiac video, the clinical practicability of intelligent screening and auxiliary diagnosis of cardiovascular diseases based on ultrasonic is improved.

The invention discloses a pulmonary vascular endothelial barrier injury model and a construction method and application thereof, and relates to the technical field of biologication.The construction method of the pulmonary vascular endothelial barrier injury model comprises the following steps that a healthy mouse is adaptively fed for one week and then anesthetized with a medicine, oncostatin M recombinant protein is pretreated and then instilled into the lung of the mouse through an airway, and then the mouse is subjected to tumor cell apoptosis; obtaining a pulmonary vascular endothelial barrier injury model; the invention further discloses a pulmonary vascular endothelial barrier injury model, application of the model in preparation of a pulmonary vascular disease research model and application of the model in preparation of drugs for treating pulmonary vascular diseases. According to the pulmonary vascular endothelial barrier injury model as well as the construction method and the application thereof provided by the invention, the oncostatin M protein is combined with an oncostatin M receptor type II on an endothelial cell to activate a downstream signal channel, so that the endothelial barrier is damaged, a clear target spot is provided for the endothelial barrier injury, and a pulmonary injury mechanism can be deeply discussed.

The present invention relates to a free base crystal form of a nitrogen-containing heterocyclic derivative, an acid salt and a crystal form thereof, a preparation method therefor, and a use thereof. In particular, the present invention relates to a free base crystal form of a compound represented by a general formula, an acid salt and a crystal form thereof, a preparation method therefor, a pharmaceutical composition containing a therapeutically effective amount of the salt or crystal form, and a use thereof as an inhibitor in the treatment of diseases such as cardiovascular disease and cerebrovascular disease.

The invention relates to the technical field of biological medicines, and provides a novel DELTP polypeptide and application thereof in improving cTnI cardiovascular medicines, and a novel polypeptide and application thereof in medicines for treating cardiovascular diseases. The polypeptide has a unique amino acid sequence and is composed of an amino acid sequence SEQ. NO: 1: Asp-Glu-Leu-Thr-Pro (DELTP), an amino acid sequence SEQ. NO: 2: Arg-His-Met-Ser-Tyr (RHMST) and the like, and the cardiovascular function is improved by adjusting the phosphorylation level of cardiac troponin I (cTnI).

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention discloses a cardiovascular disease multi-parameter joint monitoring method and system, and relates to the technical field of data processing. Comprising the following steps: monitoring multiple physiological parameters related to cardiovascular health of a patient by using wearable equipment to obtain monitoring data; preprocessing the monitoring data to obtain preprocessed monitoring data; respectively extracting time domain features, frequency domain features, nonlinear features and other statistical features from the preprocessed monitoring data to obtain multi-modal features; based on the multi-modal features, in combination with self-supervised learning of deep learning, a graph neural network and time sequence analysis, performing relation modeling, and performing data enhancement by using an adversarial generative network to obtain enhanced processing features; training a model by using marked normal and abnormal data by using feature importance scores and a random forest; and classifying real-time monitoring data by using the trained model, identifying normal and abnormal states, and obtaining an abnormal monitoring result.

The invention relates to the field of cardiovascular disease monitoring and risk assessment, in particular to a cardiovascular disease risk assessment method which is characterized by comprising the following steps: acquiring dynamic physiological feature data of a user; acquiring static physiological feature data of the user; performing feature extraction on the dynamic physiological feature data, performing normalization processing on the dynamic physiological feature data and the static physiological feature data, and generating structured input data; and inputting the structured input data into the pre-trained prediction model, and generating a cardiovascular disease risk assessment report, so that portable, accurate and easy-to-operate cardiovascular disease monitoring can be realized, the diagnosis cost is reduced, the portability is improved, and personalized cardiovascular disease risk assessment is realized.

The present disclosure, in part, provide compounds of Formula (I) that are VPS34 inhibitors, compositions, and methods of use thereof, such as in methods of treating cancer, diabetes, inflammatory diseases, neurodegenerative disorders, cardiovascular disorders, autoimmune diseases and viral infections:

The invention provides a multi-modal AI diagnosis and risk grading system, method and device suitable for vascular diseases, a medium and a program product, and provides an innovative method for cardiovascular diagnosis of old people by combining hemodynamics and structural indexes and utilizing a multi-modal deep learning framework. According to the method, the diagnosis accuracy is improved, and the prediction capability is enhanced through operable risk scoring. The method is unique in that double diagnosis of functions and structures is integrated, and compared with a traditional method focusing on single diagnosis, the method provides more comprehensive cardiovascular health assessment. Besides, the system has high applicability and expandability, can be integrated with clinical and wearable equipment, and realizes real-time monitoring and risk assessment. In the future, the system can further enlarge the diagnosis range by incorporating data such as biomarkers and the like, and shows good future adaptability.

The invention relates to 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and / or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

The invention relates to the technical field of biological medicine, in particular to application of ADAMTS13 to occlusive cardiovascular and cerebrovascular diseases. On one hand, the invention provides the biomarker ADAMTS13 for establishing the collateral circulation of the patient suffering from the occlusive cardiovascular and cerebrovascular diseases, and the biomarker ADAMTS13 can be used as a target spot for diagnosing, preventing and treating the occlusive cardiovascular and cerebrovascular diseases and can effectively predict the establishment of the collateral circulation of the patient suffering from the occlusive cardiovascular and cerebrovascular diseases and prevent the development of adverse cardiovascular events; the method has important value on clinical cardiovascular events, and can improve the survival rate of patients with occlusive vascular diseases and improve long-term prognosis; on the other hand, the invention provides an ADAMTS13 recombinant protein, the amino acid sequence of which is as shown in SEQ ID No: 1, and the ADAMTS13 recombinant protein can improve the proliferation, migration, invasion and tube forming capabilities of endothelial cells, and has important clinical application value for developing drugs for preventing and / or treating occlusive cardiovascular and cerebrovascular diseases.

The invention relates to the technical field of biological medicine, in particular to a novel polypeptide and application thereof in medicine for treating cardiovascular diseases. The polypeptide has a unique amino acid sequence, and is composed of an amino acid sequence of SEQ. NO: 1: Leu-Asn-Pro-Thr-Glu (LNPTG), an amino acid sequence of SEQ. NO: 2: Val-His-Met-Arg-Tyr (VHMRY), and the like. The polypeptide has a unique amino acid sequence, and provides a new way for the treatment of cardiovascular diseases by adjusting the activity of AMPK and improving the cardiovascular function.

The invention discloses a quinazolinone compound as well as a preparation method, a pharmaceutical composition and application thereof, and relates to the technical field of pharmaceutical chemistry. In particular to a quinazolinone compound as shown in a formula I or pharmaceutically acceptable salt, prodrug, stereoisomer, diastereoisomer, enantiomer, tautomer, solvate, salt of solvate, polymorphic substance and isotope labeled compound of the quinazolinone compound. The quinazolinone compound designed and synthesized by the invention can effectively inhibit TAK1 protein activity, achieves an excellent curative effect at a molecular level, and can be applied to preparation of medicines for treating and / or preventing inflammation, chronic fibrosis diseases, hyperproliferative diseases and cardiovascular diseases.

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

Predicting cardiovascular diseases (CVD) may be preceded by subtle changes in various health indicators that may make early predictions useful for timely intervention. The present disclosure relates to prediction of one or more diseases, particularly CVD, for a given subject by leveraging one or more machine-learning models based on longitudinal multimodal data. The techniques, as disclosed herein, may utilize the one or more machine-learning models including one or more feature generators, a temporal aggregator and a prediction model to process the longitudinal multimodal data, generating relevant features, a temporal feature vector and one or more metrics corresponding to one or more diseases associated with the subject. The generated metrics based on the current time and previous time points may be analyzed to assess whether the subject currently has or is at risk of developing one or more diseases.

The invention discloses a medical image curative effect evaluation system based on artificial intelligence, and the system is characterized in that an acquisition module obtains a clinical vascular medical image, builds an image database according to the clinical vascular medical image, and builds a high-resolution vascular three-dimensional image according to the image data in the image database; a positioning recognition module receives the blood vessel three-dimensional image and inputs the blood vessel three-dimensional image into a trained blood vessel positioning model, and the blood vessel positioning model automatically recognizes the blood vessel position and level in the blood vessel three-dimensional image; the evaluation module is used for cutting and calculating the blood vessel three-dimensional image according to the recognized blood vessel position and level and a preset size, and evaluating whether the lesion position and lesion type of the blood vessel with blood vessel stenosis, blood vessel dilatation and blood vessel thickening occur or not according to a calculation result; the technical problem that the prior art is difficult to accurately evaluate the curative effect of vascular diseases is solved.

A method for improving gut microbiota population in a subject by administering a composition comprising allulose, erythritol or a combination thereof. A method for increasing one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae by administering a composition comprising allulose, erythritol or a combination thereof. A method for preventing, treating or ameliorating a disease in a subject by administering a composition comprising allulose, erythritol or a combination thereof. The disease may be one or more of metabolic syndrome, obesity, type 2 diabetes, insulin resistance, hyperlipoproteinemia, hyperuricemia, hepatic steatosis, hypercholesterolemia, hypertriglyceridemia, irritable bowel syndrome (IBS), colon cancer, allergy, non-alcoholic fatty liver disease, inflammatory bowel disease, cardiovascular disease, or inflammation. The bacterial population may be the species Anaerostipes hadrus, Blautia obeum, Anaerobutyricum hallii, Eubacterium rectale (Agathobacter rectalis), Eubacterium callanderi, Eubacterium limosum and Eubacterium maltosivorans. A composition comprising allulose, erythritol or a combination thereof and one or more colonic bacterial populations from the families Lachnospiraceae or Eubacteriaceae is also provided. The composition may in the form of a food composition.

The invention discloses a cardiovascular disease diagnosis system based on a knowledge graph, relates to the technical field of cardiovascular disease diagnosis, and aims to solve the problem that the cardiovascular disease diagnosis accuracy is low as an existing cardiovascular disease diagnosis question-answering system cannot accurately cover complex pathological relations and treatment paths. The target entity tag and the condition entity tag are extracted from the natural language problem of the user through the large language model, the reverse reasoning path is constructed on the ontology structure of the medical knowledge graph by taking the target tag as a starting point, path pruning and optimization are performed in combination with the condition tag and semantic information, then structured query of the knowledge graph is guided, and the user experience is improved. And a final answer is generated by the large language model. According to the invention, complex pathological relations and treatment paths can be accurately covered. Compared with a traditional cardiovascular question-answering system, the technical scheme of the invention has the advantage that the accuracy is doubled or more.

Systems and methods are disclosed for evaluating a patient with vascular disease. One method includes receiving patient-specific data regarding a geometry of the patient's vasculature; creating an anatomic model representing at least a portion of a location of disease in the patient's vasculature based on the received patient-specific data; identifying one or more changes in geometry of the anatomic model based on a modeled progression or regression of disease at the location; calculating one or more values of a blood flow characteristic within the patient's vasculature using a computational model based on the identified one or more changes in geometry of the anatomic model; and generating an electronic graphical display of a relationship between the one or more values of the calculated blood flow characteristic and the identified one or more changes in geometry of the anatomic model.

The invention relates to the field of small cerebral vessels, in particular to a medical image-based early feature analysis method and system for small cerebral vessels. The method comprises the following steps: acquiring a brain magnetic resonance image data set, preliminarily analyzing brain small vessel local features based on the brain magnetic resonance image data set, and generating a basic brain small vessel feature set; obtaining a clinical parameter set of the patient, analyzing the recessive influence factors according to the clinical parameter set of the patient, and generating a brain small vessel optimized feature set based on the basic brain small vessel feature set and in combination with the recessive influence factors; and performing visual fusion rendering according to the brain small vessel optimized feature set, and generating and outputting a record analysis log. In the process of early feature analysis of small cerebral vessels, doctors are assisted in accurately identifying the enlargement of the gaps around the vessels and simulators thereof, the misjudgment risk is effectively reduced, and the accuracy and reliability of early diagnosis of small cerebral vessel diseases are improved.

The invention is applied to the technical field of health-care products, and discloses a sea-buckthorn soft capsule, which comprises a capsule shell and a content, the capsule shell is composed of gelatin, water, glycerin and an auxiliary material, the auxiliary material is a preservative or a plasticizer, the content is composed of one of seabuckthorn seed oil or fruit oil, seabuckthorn powder and an auxiliary material, the auxiliary material is one of a suspending aid and an antioxidant or a mixture of the suspending aid and the antioxidant, the seabuckthorn powder is rich in flavone, and the auxiliary material is a mixture of the suspending aid and the antioxidant. The soft capsule has the effects of lowering lipid, softening blood vessels and preventing vascular diseases. According to the hippophae rhamnoides soft capsule, a product capsule shell is prepared from gelatin, water and glycerin according to a specific proportion, it can be guaranteed that the capsule shell has proper hardness and elasticity and is convenient to process and store, hippophae rhamnoides seed (fruit) oil and hippophae rhamnoides powder in the content are matched according to a reasonable proportion, the hippophae rhamnoides powder is rich in flavone, and the hippophae rhamnoides powder and the hippophae rhamnoides seed (fruit) oil act the effects of lowering lipid, softening blood vessels and preventing vascular diseases can be better exerted.

A pharmaceutical composition comprising: (a) from about 1 to about 25 wt% AZD0780; (b) from about 60 to about 95 wt% of two or more pharmaceutical diluents; (c) from about 3 to about 5 wt% of one or more pharmaceutical disintegrants; (d) from about 0.5 to about 3 wt% of one or more pharmaceutical lubricants; (e) from 0.0 to about 5 wt% of one or more pharmaceutical glidants; and (f) from 0.0 to about 5 wt% of one or more pharmaceutical binders, wherein the component weights add up to 100 and a method of lowering LDL-C levels, reducing cardiovascular risk and / or treatment of a cardiovascular disease, comprising administering to a subject in need thereof AZD0780, or a pharmaceutically acceptable salt thereof, in a daily dose of from 1 mg to 30 mg.

The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and / or prevention of diseases and to their use for producing medicaments for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.

The invention relates to the technical field of stem cells, and particularly discloses application of mesenchymal stem cells (MSC) in treatment of lower limb vein ischemia. According to the application, the SDF1-FGF2 fusion protein is used for pretreating human mesenchymal stem cells (hMSCs), and the cell activity, the blood flow recovery capacity and the anti-inflammatory effect of the hMSCs in a lower limb vein ischemia model can be remarkably improved through pretreatment. The hMSCs pretreated by SDF1-FGF2 are injected into the body of a venous ischemia model mouse, and compared with untreated cells, the hMSCs have better effects in the aspects of improving blood perfusion, reducing inflammatory response, recovering motor function and the like. The method provides an efficient stem cell treatment strategy for vascular diseases such as lower limb vein ischemia.